Company Overview
Snapshot
Founded in February 2018 by Nadav Ben-Dov and Aviram Sariel, phenofAST operates with 1-10 employees. The company has secured funding across one round from one investor.
Business overview
phenofAST develops a rapid and cost-effective clinical diagnostic solution for antimicrobial susceptibility testing (AST). Their core technology utilizes innovative physics-based detection of cell division through laser light interferences, powered by AI analysis, to provide definitive AST results within four hours from a positive culture. This solution is designed for microbiology labs, aiming to minimize antimicrobial resistance (AMR) and improve treatment efficacy by enabling physicians to adjust antibiotic treatments on the same day of patient admission. The company targets the healthcare industry, serving laboratories, healthcare providers, and potentially insurance companies and patients.
Strategic signal
In June 2021, MindUP, a prominent Israeli digital health incubator, invested in phenofAST, highlighting the startup's bio-convergent AST solution as a critical tool against the growing threat of antimicrobial resistance. This investment signals strong validation for phenofAST's technology, particularly its ability to deliver definitive AST results for urinary tract infections in just four hours, which is crucial for improving patient outcomes and reducing AMR incidence in the healthcare sector.
Log in to access full profile ›Company Intelligence Q&A
- What is phenofAST's core technology?
- phenofAST utilizes a completely new and innovative physics-based technology that detects cell division through laser light interferences, powered by AI analysis, to deliver rapid antimicrobial susceptibility testing results.
- When was phenofAST founded and by whom?
- phenofAST was founded in February 2018 by Nadav Ben-Dov and Aviram Sariel.
- What problem does phenofAST aim to solve?
- phenofAST aims to address the challenge of slow antibiotic susceptibility testing, which typically takes 2-3 days, by providing definitive results within 4 hours. This helps combat the accelerated spread of antibiotic-resistant bacteria and reduces inappropriate antibiotic treatment.
- What is the primary benefit of phenofAST's solution for microbiology labs?
- phenofAST's solution enables microbiology labs to provide physicians with antibiotic susceptibility test results on the same day a patient is admitted, allowing for immediate adjustment of antibiotic treatment, minimizing antimicrobial resistance, and maximizing effective treatment.